Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver June 22-26 2022 Back

Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients       EASL 2022 June 22-26 London   HY Woo1, HR Lee1, YJ Park1, and J Heo1 1Department of Internal Medicine, Pusan National University School of Medicine   such as prior direct antiviral agents (DAA) failure, decompensated cirrhosis or presence of hepatocellular carcinoma (HCC).